In our series on the talented researchers working at BioMed X Institute, we asked Dr. Özdemirhan Serçin, Group Leader in BioMed X’s research team ‘SDR Synthetic Lethality in DNA Repair’ a few questions on his professional career and his work at and with BioMed X Institute. BioMed X: “First of all: Congrats on your new ..read more

AION Labs will set Israeli computing talent to solving international pharma companies' problems. CEO Mati Gill and adviser Christian Tidona explain ..read more

AION Labs will create and invest in early-stage start-ups developing AI and computational solutions to major challenges in pharma ..read more

German independent research institute BioMed X has recently announced the successful completion of the research project DNA Damage in Cancer (DDC) in collaboration with Merck KGaA, Darmstadt, Germany ..read more

BioMed X is an independant research institue located within the campus environment of the university of Heidelberg in Germany ..read more

Mati Gill’s exposure to the power of pharma collaboration can’t be overstated. During his 11 years as COO of the Global Legal Group, and later, head of government affairs, corporate & international markets at Teva Pharmaceuticals, he was exposed to virtually every aspect of the business ..read more

Successful collaboration and rich data set lead to extension of project Follow up cancer research project in Heidelberg to discover synthetic lethal interactions between DNA repair genes Heidelberg, Germany, November 2, 2021. German independent research institute BioMed X announces today the successful completion of the research project DNA Damage in Cancer (DDC) in collaboration with Merck ..read more

German independent research institute BioMed X has announced the launch of a global call for application to identify biomedical scientists and inventors to form a new startup at AION Labs’, Israel. The company spearheads the adoption of AI technologies and computational science to solve therapeutic challenges ..read more

A new lab formed by four pharmaceutical companies, a German biomedical research institute, a venture capital firm, and Amazon Web Services is creating a radically different model for drug discovery that could become a blueprint for how companies collaborate, scale AI and work with startups in future ..read more

AWS has joined pharma giants AstraZeneca, Pfizer, Merck, and Teva to launch AION Labs – an innovation hub designed to develop AI for use in drug discovery ..read more